CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Royalties	$ 58,779	$ 47,236	$ 169,415	$ 207,869
Diagnostic services	58,119	37,978	142,482	69,558
Clinical research services	6,431	3,900	8,481	35,573
Total revenues	123,329	89,114	320,378	313,000
Costs and expenses:
Cost of revenues	473,202	424,559	1,427,831	1,143,293
Research and development	1,414,706	3,937,398	6,676,251	11,221,876
Selling and marketing	419,927	2,940,862	2,442,931	9,127,450
General and administrative	3,659,587	2,710,782	9,915,359	9,183,761
Restructuring Charges	(46,472)	0	1,669,526	0
Total operating expenses	5,920,950	10,013,601	22,131,898	30,676,380
Loss from operations	(5,797,621)	(9,924,487)	(21,811,520)	(30,363,380)
Net interest expense	(16,473)	(354,993)	(877,741)	(967,522)
Gain from change in fair value of derivative financial instruments—warrants	1,528,669	88,208	2,012,747	674,834
Loss on extinguishment of debt	0	0	(1,655,825)	0
Other loss, net	(6,541)	0	(4,975)	0
Net loss	(4,291,966)	(10,191,272)	(22,337,314)	(30,656,068)
Preferred stock dividend	(6,060)	(6,060)	(18,180)	(18,180)
Net loss attributable to common stockholders	$ (4,298,026)	$ (10,197,332)	$ (22,355,494)	$ (30,674,248)
Net loss per common share - basic (in USD per share)	$ (0.12)	$ (0.34)	$ (0.68)	$ (1.02)
Net loss per common share - diluted (in USD per share)	$ (0.12)	$ (0.34)	$ (0.68)	$ (1.04)
Weighted-average shares outstanding — basic	36,465,672	30,339,774	32,826,306	30,018,841
Weighted-average shares outstanding — diluted	36,465,672	30,339,774	32,826,306	30,136,572